The antiserum was produced against synthesized peptide derived from human NCoA2 around the phosphorylation site of Ser736. AA range:702-751
Alternative Names:
NCOA2, BHLHE75, TIF2, Nuclear receptor coactivator 2, NCoA-2, Class E basic helix-loop-helix protein 75, bHLHe75, Transcriptional intermediary factor 2, hTIF2
The protein encoded by this gene functions as a transcriptional coactivator for nuclear hormone receptors, including steroid, thyroid, retinoid, and vitamin D receptors. The encoded protein acts as an intermediary factor for the ligand-dependent activity of these nuclear receptors, which regulate their target genes upon binding of cognate response elements. This gene has been found to be involved in translocations that result in fusions with other genes in various cancers, including the lysine acetyltransferase 6A (KAT6A) gene in acute myeloid leukemia, the ETS variant 6 (ETV6) gene in acute lymphoblastic leukemia, and the hes related family bHLH transcription factor with YRPW motif 1 (HEY1) gene in mesenchymal chondrosarcoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016],
Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/5000. Not yet tested in other applications.
Immunohistochemistry analysis of paraffin-embedded human breast carcinoma, using NCoA2 (Phospho-Ser736) Antibody. The picture on the right is blocked with the phospho peptide.
Western blot analysis of lysates from HeLa cells treated with TSA 400nM 24H, using NCoA2 (Phospho-Ser736) Antibody. The lane on the right is blocked with the phospho peptide.
* VAT and and shipping costs not included. Errors and price changes excepted
